|
Bio Folien Vorteile eines US-Listings Unabhängiger (!) Research von renommierten amerikanischen Banken Die sind leider auch von den Q2 Ergebnissen enttäuscht Biofrontera price target lowered to $21 from $24 at Lake Street Lake Street analyst Thomas Flaten lowered his price target for Biofrontera to $21 from $24 after the company's preliminary Q2 results came in below expectations. The analyst says that while Biofrontera confirmed it expects to maintain 2019 guidance, he reduced his 2019 estimates to reflect some uncertainty about ongoing sales trends. Flaten, however, continues to believe the long-term opportunity for the company in general, and Ameluz in particular, is strong. He keeps a Buy rating on Biofrontera. https://thefly.com/landingPageNews.php?id=2931249&headline=B… |
|
| aus der Diskussion: | Biofrontera - Heiße Turnaround-Spekulation |
| Autor (Datum des Eintrages): | Caldo (11.07.19 18:06:17) |
| Beitrag: | 50,843 von 66,537 (ID:61006028) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |